REDCARE PHARMACY NV |
Market Closed -
Other stock markets
|
After market 01:29:04 pm | |||
| 114.8 EUR | +6.10% |
|
114.5 | -0.26% |
| Jul. 02 | REDCARE PHARMACY : Jefferies gives a Buy rating | ZD |
| Jul. 02 | REDCARE PHARMACY : Sell rating from UBS | ZD |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 585.7 | 2,658 | 2,050 | 798.2 | 2,395 | 2,201 | - | - |
| Enterprise Value (EV) 1 | 621.6 | 2,568 | 2,039 | 986.6 | 2,395 | 2,364 | 2,346 | 2,294 |
| P/E ratio | -15.6 x | -127 x | -27.3 x | -10.2 x | -180 x | -223 x | 66.3 x | 36.5 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 0.84 x | 2.75 x | 1.93 x | 0.66 x | 1.33 x | 0.93 x | 0.76 x | 0.62 x |
| EV / Revenue | 0.89 x | 2.65 x | 1.92 x | 0.82 x | 1.33 x | 0.99 x | 0.81 x | 0.65 x |
| EV / EBITDA | -45.8 x | 119 x | -408 x | -123 x | 44.8 x | 33.8 x | 20.2 x | 13.5 x |
| EV / FCF | -13.8 x | -72.3 x | -64.7 x | -11.9 x | 103 x | -68.6 x | 112 x | 33.1 x |
| FCF Yield | -7.26% | -1.38% | -1.55% | -8.38% | 0.97% | -1.46% | 0.89% | 3.03% |
| Price to Book | 2.44 x | 6.91 x | 4.94 x | 2.26 x | - | 3.87 x | 3.64 x | 3.24 x |
| Nbr of stocks (in thousands) | 13,464 | 17,935 | 18,095 | 18,095 | 18,199 | 20,342 | - | - |
| Reference price 2 | 43.50 | 148.2 | 113.3 | 44.11 | 131.6 | 108.2 | 108.2 | 108.2 |
| Announcement Date | 3/17/20 | 3/3/21 | 3/2/22 | 3/7/23 | 3/5/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 701 | 968.1 | 1,060 | 1,204 | 1,799 | 2,379 | 2,914 | 3,524 |
| EBITDA 1 | -13.57 | 21.62 | -5 | -8.044 | 53.5 | 69.93 | 116.2 | 169.7 |
| EBIT 1 | -28.18 | 5.556 | -32.3 | -47.55 | -3.793 | 7.239 | 47.28 | 99.55 |
| Operating Margin | -4.02% | 0.57% | -3.05% | -3.95% | -0.21% | 0.3% | 1.62% | 2.83% |
| Earnings before Tax (EBT) 1 | -42.18 | -15.93 | -77.88 | -84.12 | -14.35 | -8.523 | 58.78 | 106.4 |
| Net income 1 | -36.27 | -16.77 | -74.2 | -77.65 | -12.04 | -9.692 | 40.31 | 69.76 |
| Net margin | -5.17% | -1.73% | -7% | -6.45% | -0.67% | -0.41% | 1.38% | 1.98% |
| EPS 2 | -2.780 | -1.170 | -4.150 | -4.320 | -0.7300 | -0.4851 | 1.631 | 2.966 |
| Free Cash Flow 1 | -45.11 | -35.53 | -31.52 | -82.64 | 23.24 | -34.43 | 20.96 | 69.42 |
| FCF margin | -6.43% | -3.67% | -2.97% | -6.86% | 1.29% | -1.45% | 0.72% | 1.97% |
| FCF Conversion (EBITDA) | - | - | - | - | 43.43% | - | 18.04% | 40.91% |
| FCF Conversion (Net income) | - | - | - | - | - | - | 52% | 99.51% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 3/17/20 | 3/3/21 | 3/2/22 | 3/7/23 | 3/5/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2021 Q4 | 2021 S2 | 2022 Q1 | 2022 Q2 | 2022 S1 | 2022 Q3 | 2022 Q4 | 2022 S2 | 2023 Q1 | 2023 Q2 | 2023 S1 | 2023 Q3 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 | 2025 Q2 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales | 534.4 | 288 | 525.9 | 305 | 287 | 592 | 284.5 | 327.8 | 612.3 | 372.1 | 419.9 | 791.9 | 475.5 | 560.2 | - | - | - | - | - |
| EBITDA | 6.9 | -10 | -11.9 | -4 | -5 | -9 | 1.256 | 1.133 | 2.389 | 8.763 | 13.25 | 22.01 | 15.25 | 11.75 | - | - | - | - | - |
| EBIT | - | -18.6 | - | - | - | - | -9.509 | - | - | - | - | - | -21.64 | - | - | - | - | - | - |
| Operating Margin | - | -6.46% | - | - | - | - | -3.34% | - | - | - | - | - | -4.55% | - | - | - | - | - | - |
| Earnings before Tax (EBT) | - | -46.24 | - | - | - | - | - | - | - | - | - | - | 8.899 | - | - | - | - | - | - |
| Net income 1 | - | -42.5 | - | - | - | - | - | - | - | - | - | - | 9.11 | - | -1.729 | -2.402 | -4.035 | - | - |
| Net margin | - | -14.76% | - | - | - | - | - | - | - | - | - | - | 1.92% | - | - | - | - | - | - |
| EPS 2 | - | -2.350 | - | - | - | - | - | - | - | - | - | - | - | - | -0.0856 | -0.1189 | -0.1997 | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 8/5/21 | 3/2/22 | 3/2/22 | 5/5/22 | 8/3/22 | 8/3/22 | 10/31/22 | 3/7/23 | 3/7/23 | 5/2/23 | 8/1/23 | 8/1/23 | 10/31/23 | - | - | - | - | - | - |
1EUR in Million2EUR
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 36 | - | - | 188 | - | 163 | 145 | 93.3 |
| Net Cash position 1 | - | 90 | 11 | - | - | - | - | - |
| Leverage (Debt/EBITDA) | -2.65 x | - | - | -23.42 x | - | 2.326 x | 1.25 x | 0.55 x |
| Free Cash Flow 1 | -45.1 | -35.5 | -31.5 | -82.6 | 23.2 | -34.4 | 21 | 69.4 |
| ROE (net income / shareholders' equity) | -16.2% | -5.1% | -17.7% | -20.2% | - | 0.31% | 6.55% | 11.5% |
| ROA (Net income/ Total Assets) | -9.33% | -3.5% | -11.2% | -10.3% | - | -0.2% | 4.19% | 6.42% |
| Assets 1 | 388.9 | 479.2 | 660.1 | 756.3 | - | 4,744 | 962.4 | 1,086 |
| Book Value Per Share 2 | 17.80 | 21.50 | 23.00 | 19.50 | - | 28.00 | 29.70 | 33.30 |
| Cash Flow per Share 2 | -2.320 | 1.240 | 0.6500 | -1.620 | 3.190 | 3.260 | 3.920 | 7.170 |
| Capex 1 | 14.7 | 53.3 | 43.2 | 53.5 | 38.2 | 56.5 | 63.9 | 66.7 |
| Capex / Sales | 2.1% | 5.51% | 4.07% | 4.44% | 2.12% | 2.38% | 2.19% | 1.89% |
| Announcement Date | 3/17/20 | 3/3/21 | 3/2/22 | 3/7/23 | 3/5/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
108.2
EUR
Average target price
148.8
EUR
Spread / Average Target
+37.55%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -17.78% | 2.36B | |
| -44.50% | 8.55B | |
| -25.00% | 6.38B | |
| -6.21% | 6.06B | |
| +87.87% | 4.97B | |
| -4.23% | 4.55B | |
| +3.33% | 4.3B | |
| -25.10% | 4.17B | |
| -19.83% | 2.53B | |
| +150.93% | 2.44B |
- Stock Market
- Equities
- RDC Stock
- Financials Redcare Pharmacy NV
